Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Ophthalmic Consultants of Long Island Allergan |
---|---|
Information provided by: | Ophthalmic Consultants of Long Island |
ClinicalTrials.gov Identifier: | NCT00348335 |
The purpose of this study is to determine whether Restasis (topical cyclosporin) is effective in the treatment of ocular rosacea
Condition | Intervention | Phase |
---|---|---|
Rosacea |
Drug: Cyclosporin 0.05% Ophthalmic Solution |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea |
Estimated Enrollment: | 50 |
Study Start Date: | June 2006 |
Estimated Study Completion Date: | September 2007 |
The study is designed to compare the efficacy of topical cyclosporin (Restasis) with that of Refresh Endura for the treatment of the signs and symptoms of ocular rosacea in patients presently controlled on topical corticosteroids
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: John R Wittpenn | 631-941-1400 | jwittpenn@ocli.net |
Contact: Stacey Kruck | 631-941-1400 | skruck@ocli.net |
United States, New York | |
2500 Rte 347 Bldg 24 | Recruiting |
StonyBrook, New York, United States, 11790 | |
Principal Investigator: John R Wittpenn |
Principal Investigator: | John R Wittpenn, MD | Ophthalmic Consultants of Long Island |
Study ID Numbers: | 32,133 |
Study First Received: | June 30, 2006 |
Last Updated: | March 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00348335 |
Health Authority: | United States: Institutional Review Board |
Rosacea Cyclosporine Skin Diseases Clotrimazole |
Miconazole Tioconazole Cyclosporins |
Anti-Infective Agents Immunologic Factors Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antifungal Agents Physiological Effects of Drugs |
Enzyme Inhibitors Antirheumatic Agents Dermatologic Agents Immunosuppressive Agents Pharmacologic Actions |